Jaclyn Sharp

Founder/CEO @IMIMPOSTER - Products that Save Animals. Making this world a better place for the voiceless. #IMPOSTER #BCorp #socent

[Jaclyn Sharp @JaclynSharpNYC]

My company's @IMImposter story & mission 💚❤️💙🐾🐴 https://t.co/6tXee6j2Bd

[IMPOSTER 4 Animals @IMImposter]

IMPOSTER's full video introduction and story 🐾 #IMPOSTER4animals #veganfashion #socent #fauxfur #vegan #CrueltyFree https://t.co/biX5IScA1a

[Humane World for Animals @humaneworldorg]

We've dedicated over a decade to ending the dog meat industry in South Korea—and this work is paying off. We've shut down dog meat farms, rescued nearly 2,800 dogs and worked with policymakers to phase out the dog meat industry entirely by 2027.

This is great progress, but there's still so much work to do in other countries for so many cats and dogs like Peach.

Sign our pledge to help us end the dog and cat meat trade around the world: https://t.co/9mSEbtIZbm

[Humane World for Animals @humaneworldorg]

Camera Nazionale della Moda Italiana (CNMI), the exclusive owner of the “Milano Fashion Week®”, announced today that it will no longer promote fur at any official Milan Fashion Week event, including on social media.

Learn More: https://t.co/JnTDpe5Ndy

[Humane World for Animals @humaneworldorg]

Say no to real fur. Choosing faux fur protects foxes from being trapped and suffering for fashion.

[Kitty Block @humaneworldkb]

What should you do if you see a cat outside? It depends. From owned pets to community cats, research shows there’s no one-size-fits-all answer. https://t.co/IjhXF5UJuZ

[Kitty Block @humaneworldkb]

The M-44 cyanide trap is making a comeback on public lands putting wildlife, pets and people at risk. We have better, humane alternatives for managing human-wildlife conflict. This is a step backward.

#AnimalWelfare #PublicSafety
https://t.co/Zy8keObhhR

[Kitty Block @humaneworldkb]

Twenty years after the first #DevilWearsPrada, fashion has changed. Prada, Vogue, New York Fashion Week and many others dropped fur since Andy Sachs first met Miranda Priestly in 2006. https://t.co/UKsRv20WT8

[Jaclyn Sharp @JaclynSharpNYC]

@elonmusk Rescuing horses helps with happiness. They are wonderful animals for kids to be around too.

[Jaclyn Sharp @JaclynSharpNYC]

@NatashaCL7 @femmyjimmy @elonmusk When women’s education goes up, the birth rate goes way down. It also has to do with choices and access to contraception. From what I have read, the most significant factor is education.

[Dr. Pat Soon-Shiong @DrPatrick]

Initial data shows 2 patients with near Complete Response & 100% disease control in first 5 patients. When the immune system is protected, CR in tumors difficult to treat in recurrent GBM is possible. GBM trial open at https://t.co/wwLWOlBYtC

Data for lung cancer next #WCLC25

[David Din, CFA @DavidDin]

STUNNING LONG-TERM SURVIVAL OF FORMER END-STAGE CANCER PATIENTS – WHILE FDA STALLS BROADER APPROVALS

$IBRX

I've been following @ImmunityBio for a while now, and every time I dive deeper, I'm blown away by the real-world impact of their BioShield platform—anchored by ANKTIVA. This isn't just another drug; it's a paradigm shift in how we fight cancer by supercharging the immune system instead of destroying it like chemo or radiation. And today, I want to shine a light on the stories of long-term survivors that prove this could be as close to a cure as we've ever seen��not just for cancer, but potentially for long COVID too, where immune dysfunction plays a huge role.

Look at this image: It features Larry, cancer-free for 9+ years after battling end-stage disease; Elvira, thriving 10+ years later as a nurse; and David, still driving and enjoying life 9+ years on. Even Dr. Charles Rosser from Cedars-Sinai, with over 20 years in urology, says he's never seen such durable results in a clinical trial. These aren't anomalies—they're the result of ANKTIVA restoring natural killer cells, T cells, and memory T cells to "eat" cancer from the outside, creating lasting immunity.

What makes these stories even more dramatic? These patients were all end-stage, near death, and had failed every available treatment—chemo, radiation, BCG, you name it. ANKTIVA was their last resort under expanded access or in trials for refractory cases, like BCG-unresponsive bladder cancer or solid tumors with immune collapse post-first-line therapies. No options left, yet here they are, alive and kicking years later. That's the power of rebuilding the immune system when everything else has failed.

And there's the video from @drpatrick himself, showing patients alive and well with excellent quality of life after 10+ years. T-cell memory in action—the immune system finally winning the war.

These stories aren't isolated. In bladder cancer trials, ANKTIVA plus BCG achieved unmatched long-term bladder preservation: over 80% of responders stayed disease-free for 36 months, with a 58% disease-free survival at 12 months and median of 25 months. For non-small cell lung cancer, combining ANKTIVA with checkpoint inhibitors showed positive long-term survival, with 27% of patients surviving beyond 2 years in advanced cases. Even in brutal pancreatic cancer, reversing lymphopenia (low white blood cells) with ANKTIVA led to a median survival of 10 months in third- to sixth-line patients, and one case study showed a patient cancer-free for over 6 years. Patients like Justin, an outdoorsman with non-muscle invasive bladder cancer, are back to full lives post-ANKTIVA.

For long COVID, the BioShield addresses persistent viral issues by clearing the virus and restoring immune competence—similar to how it tackles cancer's root cause: a dysfunctional immune system. If you're dealing with lingering symptoms or haven't heard of this, it's time to look closer. Billions suffer without knowing solutions like this exist.

The FDA has greenlit some approvals: ANKTIVA for BCG-unresponsive non-muscle invasive bladder cancer (a breakthrough designation), and expanded access for lymphopenia in solid tumors. Lymphopenia is key—it's the immune deficiency from chemo/radiation that lets cancer thrive, and ANKTIVA reverses it, opening doors for many cancers. RMAT designation for ANKTIVA plus CAR-NK in lymphopenia further accelerates paths for pancreatic and multiply relapsed patients.

But here's the fishy part: Since a potential cure for cancer had never seemed likely, the FDA has never truly focused on long-term survival—the most important metric of all—which ends up being ignored in favor of short-term surrogates like tumor shrinkage or progression-free survival. The system is built around chemotherapy and radiation, which can halt cancer short-term but ultimately lead to most patients dying from relapse or side effects. Meanwhile, innovative immunotherapies like ANKTIVA deliver durable, cure-like outcomes, yet the FDA refused to file a supplemental BLA for papillary NMIBC, despite prior guidance to submit and strong data showing it was "in the pocket." With all these positive results—long-term survivors, bladder preservation rates topping the field, survival boosts in deadly cancers—why isn't the FDA stepping up for urgent, broader approvals? Lives are on the line, and delays feel like favoritism toward Big Pharma's outdated treatments. We need more transparency and speed.

Meanwhile, the stock? Share price hovering around $2-3, market cap a laughable ~$2B for a company poised to disrupt a $90B+ cancer drug market. Insiders are buying heavily, and with international rollouts (like UK approval for ANKTIVA+BCG) and partnerships (Saudi for BioShield), this has massive upside—potentially 10x or more as awareness grows. It's undervalued because most haven't heard the full story yet.

If you're new to ImmunityBio, do your DD. This could change everything for cancer and long COVID patients. THERE CAN BE ONLY ONE—@ImmunityBio leading the way. Let's spread the word!

@drpatrick @ImmunityBio

[GretchMick @GretchMick]

Post Bioshield Test Results! #cancersurveillance #cancer #coloncancer #chemo #bioshield $IBRX @ImmunityBio @CCAlliance

[Jaclyn Sharp @JaclynSharpNYC]

@drpatrick Amazing result! Please ask Sandy about the email I sent last night. Your institute should parter with Dr Salerno on the East Coast, if possible. They have one location in Manhattan and another in Connecticut. Amazing doctor and family owned practice. https://t.co/OvoOF6qJ9l

[Jaclyn Sharp @JaclynSharpNYC]

@drpatrick

[Jaclyn Sharp @JaclynSharpNYC]

@drpatrick I emailed Sandy with this information last night. This is the doctor you should parter with immediately on the East Coast, if possible. They have one location in Manhattan and another in Connecticut. Amazing doctor and family owned practice. https://t.co/OvoOF6qJ9l

[Elon Musk @elonmusk]

Seriously 🤦‍♂️

[Jaclyn Sharp @JaclynSharpNYC]

@realDonaldTrump That being said, I’m so grateful that you were able to get a ceasefire in place.

[Jaclyn Sharp @JaclynSharpNYC]

@realDonaldTrump What about the Symington Amendment of the U.S. Foreign Assistance Act of 1961?
• Israel has publicly stated that they have nuclear weapons… I believe it’s illegal by US law to provide military aid.

[Jaclyn Sharp @JaclynSharpNYC]

@ct4rfkjr Lastly, if you have DeepSeek RI (the AI tool), ask it this question:

Can dmso help mitigate damage from radiation?

[Jaclyn Sharp @JaclynSharpNYC]

@ct4rfkjr If you have any contact information for his office, I would love to make sure they are aware of DMSO, & all its beneficial properties. If not, I will try to contact the office in a few weeks. Thank you! It isn’t widely known, because large pharmaceutical companies can’t make $$$

[Jaclyn Sharp @JaclynSharpNYC]

@ct4rfkjr So of note:

https://t.co/rbrQ02ZubY